Why is Windlas Biotech falling/rising?

As of 31-Jul, Windlas Biotech Ltd is currently priced at Rs 997.35, reflecting an increase of Rs 2.95, or 0.3%. The stock has shown a positive performance today, outperforming its sector by 1.79%. Despite touching an intraday low of Rs 944.05, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has gained 1.87%, and over the past month, it has risen by 12.45%, contrasting sharply with the Sensex, which has declined by 1.22% and 3.00% over the same periods, respectively. However, there is a notable decline in investor participation, with delivery volume dropping by 70.99% against the 5-day average. The company maintains a low debt-to-equity ratio and has shown consistent returns over the last three years, although its operating profit growth has been modest.
In the broader market context, Windlas Biotech's recent performance stands out as it has outperformed the benchmark Sensex in both the short-term and long-term, with a 21.65% return over the past year compared to the Sensex's decline of 0.68%. This indicates that while the stock is currently experiencing upward movement, there are concerns regarding its long-term growth potential, as evidenced by flat results and low cash reserves. The stock is trading at a premium compared to its peers, which may affect investor sentiment moving forward. Overall, the combination of strong short-term performance and concerns about long-term growth creates a complex picture for Windlas Biotech's stock movement.